🎉 M&A multiples are live!
Check it out!

MetaVia Valuation Multiples

Discover revenue and EBITDA valuation multiples for MetaVia and similar public comparables like Vivoryon Therapeutics, Galapagos, and Pharming.

MetaVia Overview

About MetaVia

MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.


Founded

2014

HQ

United States of America
Employees

9

Website

metaviatx.com

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$44K

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

MetaVia Financials

MetaVia has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, MetaVia achieved revenue of n/a and an EBITDA of -$28.8M.

MetaVia expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See MetaVia valuation multiples based on analyst estimates

MetaVia P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$12.5M -$28.8M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$14.0M -$12.5M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

MetaVia Stock Performance

As of April 15, 2025, MetaVia's stock price is $2.

MetaVia has current market cap of $15.9M, and EV of $44K.

See MetaVia trading valuation data

MetaVia Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$44K $15.9M XXX XXX XXX XXX $-2.95

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

MetaVia Valuation Multiples

As of April 15, 2025, MetaVia has market cap of $15.9M and EV of $44K.

MetaVia's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate MetaVia's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for MetaVia and 10K+ public comps

MetaVia Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $44K XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -0.0x XXX XXX XXX
P/E -0.6x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -0.0x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get MetaVia Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

MetaVia Valuation Multiples

MetaVia's NTM/LTM revenue growth is n/a

MetaVia's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $3.2M for the same period.

Over next 12 months, MetaVia's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate MetaVia's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for MetaVia and other 10K+ public comps

MetaVia Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 131% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $3.2M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

MetaVia Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

MetaVia M&A and Investment Activity

MetaVia acquired  XXX companies to date.

Last acquisition by MetaVia was  XXXXXXXX, XXXXX XXXXX XXXXXX . MetaVia acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by MetaVia

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About MetaVia

When was MetaVia founded? MetaVia was founded in 2014.
Where is MetaVia headquartered? MetaVia is headquartered in United States of America.
How many employees does MetaVia have? As of today, MetaVia has 9 employees.
Who is the CEO of MetaVia? MetaVia's CEO is Mr. Hyung Heon Kim.
Is MetaVia publicy listed? Yes, MetaVia is a public company listed on NAS.
What is the stock symbol of MetaVia? MetaVia trades under MTVA ticker.
When did MetaVia go public? MetaVia went public in 2016.
Who are competitors of MetaVia? Similar companies to MetaVia include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of MetaVia? MetaVia's current market cap is $15.9M
Is MetaVia profitable? Yes, MetaVia is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.